Dr Linda Mileshkin speaks to ecancer about the OUTBACK trial. Initially, she talks about the background of the study.
Dr Mileshkin explains that despite chemoradiation, the standard treatment for locally advanced cervical cancer, a significant percentage of women relapse and die of distant metastatic disease. The international randomised phase III OUTBACK trial was designed to determine the effects on survival of giving adjuvant chemotherapy after chemoradiation.
Dr Mileshkin then discusses the methodology and results of the trial. The findings from the study showed that women with locally advanced cervical cancer receiving adjuvant chemotherapy after standard cisplatin-based chemoradiation did not experience improved overall or progression-free survival. In addition, the therapy was associated with increased side effects. In the end, she mentions the future impact of this study.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.